|
1
|
Tillett WS and Francis T: Serological
reactions in pneumonia with a non-protein somatic fraction of
pneumococcus. J Exp Med. 52:561–571. 1930. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koo AS, Armstrong C, Bochner B,
Shimabukuro T, Tso CL, deKernion JB and Belldegrum A: Interleukin-6
and renal cell cancer: Production, regulation, and growth effects.
Cancer Immunol Immunother. 35:97–105. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oya M, Takayanagi A, Horiguchi A, Mizuno
R, Ohtsubo M, Marumo K, Shimizu N and Murai M: Increased nuclear
factor-kappa B activation is related to the tumor development of
renal cell carcinoma. Carcinogenesis. 24:377–384. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Blay JY, Negrier S, Combaret V, Attali S,
Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM,
Moskovtchenko JF, et al: Serum level of interleukin 6 as a
prognosis factor in metastatic renal cell carcinoma. Cancer Res.
52:3317–3322. 1992.PubMed/NCBI
|
|
6
|
Saito K and Kihara K: Role of C-reactive
protein in urological cancers: A useful biomarker for predicting
outcomes. Int J Urol. 20:161–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili
R, Bjarnason GA, et al: Overall survival and updated results for
sunitinib compared with interferon alfa in patients with metastatic
renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fujita T, Iwamura M, Ishii D, Tabata K,
Matsumoto K, Yoshida K and Baba S: C-reactive protein as a
prognostic marker for advanced renal cell carcinoma treated with
sunitinib. Int J Urol. 19:908–913. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yasuda Y, Saito K, Yuasa T, Kitsukawa S,
Urakami S, Yamamoto S, Yonese J, Takahashi S and Fukui I:
Prognostic impact of pretreatment C-reactive protein for patients
with metastatic renal cell carcinoma treated with tyrosine kinase
inhibitors. Int J Clin Oncol. 18:884–889. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Beuselinck B, Vano YA, Oudard S, Wolter P,
De Smet R, Depoorter L, Teghom C, Karadimou A, Zucman-Rossi J,
Debruyne PR, et al: Prognostic impact of baseline serum C-reactive
protein in patients with metastatic renal cell carcinoma (RCC)
treated with sunitinib. BJU Int. 114:81–89. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Teishima J, Kobatake K, Hayashi T, Seno Y,
Ikeda K, Nagamatsu H, Hieda K, Shoji K, Miyamoto K, Inoue S, et al:
Prognostic significance of C-reactive protein in patients with
intermediate-risk metastatic renal cell carcinoma treated with
molecular targeted therapy. Oncol Lett. 8:881–885. 2014.PubMed/NCBI
|
|
13
|
Fujikawa K, Matsui Y, Oka H, Fukuzawa S
and Takeuchi H: Serum C-reactive protein level and the impact of
cytoreductive surgery in patients with metastatic renal cell
carcinoma. J Urol. 162:1934–1937. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tatokoro M, Saito K, Iimura Y, Fujii Y,
Kawakami S and Kihara K: Prognostic impact of postoperative
C-reactive protein level in patients with metastatic renal cell
carcinoma undergoing cytoreductive nephrectomy. J Urol.
180:515–519. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saito K, Tatokoro M, Fujii Y, Iimura Y,
Koga F, Kawakami S and Kihara K: Impact of C-reactive protein
kinetics on survival of patients with metastatic renal cell
carcinoma. Eur Urol. 55:1145–1154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ito K, Yoshii H, Sato A, Kuroda K, Asakuma
J, Horiguchi A, Sumitomo M and Asano T: Impact of postoperative
C-reactive protein level on recurrence and prognosis in patients
with N0M0 clear cell renal cell carcinoma. J Urol. 186:430–435.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shinohara N, Kumagai A, Kanagawa K,
Maruyama S, Abe T, Sazawa A and Nonomura K: Multicenter phase II
trial of combination therapy with meloxicam, a cox-2 inhibitor, and
natural interferon-alpha for metastatic renal cell carcinoma. Jpn J
Clin Oncol. 39:720–726. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lamb GW, McMillan DC, Ramsey S and
Aitchison M: The relationship between the preoperative systemic
inflammatory response and cancer-specific survival in patients
undergoing potentially curative resection for renal clear cell
cancer. Br J Cancer. 94:781–784. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ito K, Asano T, Yoshii H, Satoh A,
Sumitomo M and Hayakawa M: Impact of thrombocytosis and C-reactive
protein elevation on the prognosis for patients with renal cell
carcinoma. Int J Urol. 13:1365–1370. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Komai Y, Saito K, Sakai K and Morimoto S:
Increased preoperative serum C-reactive protein level predicts a
poor prognosis in patients with localized renal cell carcinoma. BJU
Int. 99:77–80. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Karakiewicz PI, Hutterer GC, Trinh QD,
Jeldres C, Perrotte P, Gallina A, Tostain J and Patard JJ:
C-reactive protein is an informative predictor of renal cell
carcinoma-specific mortality: A European study of 313 patients.
Cancer. 110:1241–1247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Atzpodien J, Royston P, Wandert T and
Reitz M: DGCIN-German Cooperative Renal Carcinoma
Chemo-Immunotherapy Trials Group: Metastatic renal carcinoma
comprehensive prognostic system. Br J Cancer. 88:348–353. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Casamassima A, Picciariello M, Quaranta M,
Berardino R, Ranieri C, Paradiso A, Lorusso V and Guida M:
C-reactive protein: A biomarker of survival in patients with
metastatic renal cell carcinoma treated with subcutaneous
interleukin-2 based immunotherapy. J Urol. 173:52–55. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gauldie J, Richards C, Harnish D, Lansdorp
P and Baumann H: Interferon beta 2/B-cell stimulatory factor type 2
shares identity with monocyte-derived hepatocyte-stimulating factor
and regulates the major acute phase protein response in liver
cells. Proc Natl Acad Sci USA. 84:7251–7255. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miki S, Iwano M, Miki Y, Yamamoto M, Tang
B, Yokokawa K, Sonoda T, Hirano T and Kishimoto T: Interleukin-6
(IL-6) functions as an in vitro autocrine growth factor in renal
cell carcinomas. FEBS Lett. 250:607–610. 1989. View Article : Google Scholar : PubMed/NCBI
|
